Research
Hormonal
Semaglutide is the predominant GLP-1 RA in Brazil, driving the majority of sales growth and adverse event reports, with significant off-label use for weight loss.
Semaglutide is the most widely used GLP-1 drug in Brazil. A significant portion of its use is off-label for weight loss, which generates specific adverse event reports and requires careful monitoring.
ModerateSupportsMEDIUM confidence
Semaglutide emerged as the predominant GLP-1 RA in the Brazilian market... semaglutide-related AEs explicitly associated with off-label use were proportionally higher in Brazil than in the WHO global database.
Why this rating
Based on administrative sales and pharmacovigilance data, subject to reporting biases.
Source
<scp>GLP</scp> ‐1 Receptor Agonists in Brazil: Landscape of Consumption, Safety and Regulation
Renato Lopes Hurtado et al. · Diabetes Obesity and Metabolism · 2026
DOI 10.1111/dom.70609
cross_sectional
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- There are confirmed cases of falsified GLP-1 receptor agonists in Brazil, indicating supply chain vulnerabilities.Good
- GLP-1 receptor agonist consumption in Brazil is driven by socioeconomic capacity and access rather than epidemiological need, as evidenced by a significant positive correlation with GDP per capita and no correlation with obesity prevalence.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →